Imiquad Cream: Clinically Proven Topical Immunotherapy for Skin Conditions
Imiquad Cream
| Product dosage: 12.5mg | |||
|---|---|---|---|
| Package (num) | Per sachet | Price | Buy |
| 12 | $5.00 | $60.00 (0%) | 🛒 Add to cart |
| 24 | $3.33 | $120.00 $80.00 (33%) | 🛒 Add to cart |
| 36 | $3.06 | $180.00 $110.00 (39%) | 🛒 Add to cart |
| 60 | $2.83 | $300.00 $170.00 (43%) | 🛒 Add to cart |
| 96 | $2.60
Best per sachet | $480.00 $250.00 (48%) | 🛒 Add to cart |
Similar products
Imiquad Cream (imiquimod 5%) is a prescription-only topical immunomodulator indicated for the treatment of external genital and perianal warts, superficial basal cell carcinoma, and actinic keratosis. It works by stimulating the local immune response, enabling the body to target and eliminate abnormal skin cells and viral infections. This cream represents a non-invasive therapeutic option with demonstrated efficacy across multiple dermatological indications, offering patients an alternative to surgical or destructive procedures. Proper application and adherence to medical guidance are essential for optimal outcomes and minimal adverse effects.
Features
- Contains 5% imiquimod as the active pharmaceutical ingredient
- Available in single-use sachets or multi-use packets (250 mg each)
- White-to-light yellow oil-in-water emulsion base
- pH-balanced formulation for cutaneous compatibility
- Preservative-free in single-dose packaging
- Stable at room temperature (15–30°C)
Benefits
- Induces localized immune activation to target abnormal cells
- Provides a non-surgical treatment option for certain skin cancers and pre-cancers
- Reduces recurrence rates of genital warts compared to destructive methods
- Allows self-application under medical supervision
- Minimizes scarring risk compared to excision or ablation
- Suitable for sensitive or hard-to-treat anatomical areas
Common use
Imiquad Cream is commonly prescribed for the management of external anogenital warts caused by human papillomavirus (HPV), particularly in immunocompetent adults. It is also approved for the treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in adults with normal immune function, when surgical methods are less appropriate. Additionally, it is indicated for actinic keratosis on the face or scalp in adults. Clinical use should always follow confirmed diagnosis and risk-benefit assessment by a healthcare provider.
Dosage and direction
Apply a thin layer of Imiquad Cream to the treatment area, rubbing in until the cream is no longer visible. Use prior to normal sleeping hours and leave on the skin for 6–10 hours before washing with mild soap and water. Frequency depends on indication:
- External genital/perianal warts: Apply 3 times per week (e.g., Monday, Wednesday, Friday) for up to 16 weeks.
- Superficial basal cell carcinoma: Apply 5 times per week for 6 weeks.
- Actinic keratosis: Apply 2 times per week for 16 weeks.
Avoid excessive application. Do not use occlusive dressings. Wash hands before and after use.
Precautions
- For external use only. Avoid contact with eyes, lips, and nostrils.
- Not recommended for mucosal surfaces or intra-anal/vaginal use.
- Sexual contact should be avoided while the cream is on the skin.
- Sun exposure should be minimized during treatment.
- Use with caution in immunocompromised patients.
- Not intended for use in children or adolescents under 18 years.
- May cause local skin reactions; temporary discontinuation may be necessary if severe.
Contraindications
- Hypersensitivity to imiquimod or any component of the formulation.
- Use on broken, inflamed, or recently treated skin (e.g., after cryotherapy or surgery).
- Autoimmune disorders or those undergoing immunosuppressive therapy.
- Pregnancy and breastfeeding (unless clearly needed and under strict supervision).
Possible side effects
Very common (≥10%): local skin reactions including erythema, edema, itching, burning, scaling, flaking, erosions, and ulceration.
Common (1–10%): headache, fatigue, fever, myalgia, influenza-like symptoms.
Uncommon (<1%): regional lymph node enlargement, hypopigmentation or hyperpigmentation.
Rare: severe local reactions with scarring, systemic allergic reactions.
Drug interaction
No formal drug interaction studies have been conducted. However, concomitant use with other topical products (corticosteroids, retinoids) may increase irritation or affect efficacy. Avoid using other topical medications on the same area unless directed by a physician.
Missed dose
Apply as soon as remembered, unless it is nearly time for the next dose. Do not double the dose. Resume regular schedule.
Overdose
Excessive application may intensify local skin reactions and increase systemic absorption. There is no specific antidote. Treatment should be symptomatic and supportive. Wash the area thoroughly with soap and water. Seek medical attention if systemic symptoms (e.g., fever, fatigue) occur.
Storage
Store below 30°C. Do not freeze. Keep sachets in the original outer carton to protect from light. Keep out of reach of children. Discard any opened sachet after use; do not reuse.
Disclaimer
This information is intended for healthcare professionals and educated patients under medical supervision. It does not replace professional medical advice, diagnosis, or treatment. Always follow the guidance of your prescribing physician and refer to the official prescribing information for complete details.
Reviews
Clinical studies and post-marketing surveillance support the efficacy and acceptable safety profile of Imiquad Cream when used as directed. In trials, complete clearance of external genital warts was observed in 50–60% of patients. For superficial basal cell carcinoma, histologic clearance was achieved in approximately 80% of cases. Patient satisfaction is generally high due to the non-invasive nature of treatment, though local skin reactions are frequently reported and often manageable.